A capital investment firm is attempting to buy 1.5 million shares of AbbVie common stock at $88.05 per share in a mini-tender offer.
What you should know:
1. TRC Capital Investment Corp., has turned its eye to AbbVie as the latest target of its mini-tender investment strategy. The firm has developed a reputation for its mini-tender investment strategy, where it attempts to secure a small minority ownership by buying stock for under-market value, according to an article on Seeking Alpha.
2. AbbVie released a statement recommending shareholders don't sell to TRC.
3. AbbVie recommends shareholders obtain current share quotes, review terms and conditions, and consult with their stockbroker before taking any action.